Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride

Healthy Adults Clinical Trial

Official title:

Bioavailability of Fish Oils: Emulsified vs. Capsular Triglyceride

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01488747
• Other study ID #: GFHNRC023
• Status: Completed
• Phase: N/A
• Start date: November 2011
• Est. completion date: April 2016

Study information

• Verified date: August 2018
• Source: USDA Grand Forks Human Nutrition Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this investigation is to determine the relative percentage and rate of incorporation of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total omega-3 (n-3) fatty acids after ingestion of 4 emulsified flavored triglyceride fish oil supplements versus an encapsulated triglyceride in defined plasma lipid pools.

The primary endpoints to be evaluated include the fatty acid composition of plasma lipids before and after consumption of a single dose of emulsified triglyceride based fish oil and triglyceride of similar n-3 compositions in capsule form. The investigators will measure changes in plasma phospholipid, and chylomicron fatty acids.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: April 2016
• Est. primary completion date: October 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Healthy adults ages 18 to 60.

2. Body mass index between 22 and 32 kg/m2.

3. Medical history (interview) demonstrating good health.

4. Nonsmoker.

5. Consumption of a typical American diet with no unusual dietary habits.

6. Willingness to comply with the study protocol.

7. Low reported n-3 intake (<100 mg/d) on the Omega-3 Checklist

Exclusion Criteria:

1. Any active, uncontrolled medical problem.

2. Consumption of essential fatty acid supplements within the past 6 months.

3. Use of lipid lowering drugs.

4. Fish consumption greater than 1 fish meal per week

Related Conditions & MeSH terms

• Healthy Adults

Intervention

Dietary Supplement:
• Coromega Omega-3 Squeeze
660 mg EPA, 434 mg DHA
• Coromega Nectar
660 mg EPA, 436 mg DHA
• Barleans Swirl
660 mg EPA, 660 mg DHA
• Nordic Omega-3 Softgel
660 mg EPA, 440 mg DHA

Locations

Country	Name	City	State
United States	USDA Grand Forks Human Nutrition Research Center	Grand Forks	North Dakota

Sponsors (1)

Lead Sponsor	Collaborator
USDA Grand Forks Human Nutrition Research Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Raatz SK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM. Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil. J Am Diet Assoc. 2009 Jun;109(6):1076-81. doi: 10.1016/j.jada.2009.03.006. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the curve for phospholipid fatty acids	Evaluation of the bioavailability of fatty acids from fish oil supplements	48 hours
Secondary	Area under the curve for chylomicron fatty acids	Evaluation of the bioavailability of fatty acids from fish oil supplements	48 hours

External Links

•   USDA Grand Forks Human Nutrition Research Center